The results for CD8+ T cells within the tumor (Fig. 4, Left side) show that, above the therapeutic threshold of CAR-T cell dose, delaying the time of injection leads to a reduced number of CD8+ T cells in the tumor. This evidence concerns the gene CD8A and neoplasm.